Germany
Japan
United Kingdom
China
Primary Antibodies
HADH mouse monoclonal antibody,clone UMAB151
| Applications | 10k-ChIP, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
DDX56 mouse monoclonal antibody,clone UMAB152
| Applications | 10k-ChIP, IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
DDX56 mouse monoclonal antibody,clone UMAB153
| Applications | 10k-ChIP, IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
Vimentin (VIM) mouse monoclonal antibody,clone UMAB159
| Applications | IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
Vimentin (VIM) mouse monoclonal antibody,clone UMAB160
| Applications | IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
TTF1 (NKX2-1) mouse monoclonal antibody,clone UMAB162
| Applications | IHC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
CDH1 mouse monoclonal antibody,clone UMAB184
| Applications | 10k-ChIP, FC, IF, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 180.00
In Stock
USD 180.00
In Stock
Active filters
Clonalities
- Monoclonal
Conjugates
- Unconjugated
Filter by
Target Symbol
- VSNL1 (165)
- ALK (163)
- KLK8 (155)
- CD4 (147)
- PDCD1 (146)
- TP53 (133)
- MAP2K1 (131)
- ERBB2 (127)
- CD5 (125)
- CDKN2A (111)
- PGR (106)
- NME1 (105)
- ABCB1 (98)
- JUN (97)
- CD274 (95)
- ERCC1 (95)
- MKI67 (95)
- EGFR (92)
- KRT19 (92)
- GLI1 (91)
- PECAM1 (91)
- MAP2K3 (90)
- EPCAM (86)
- TG (85)
- CD40 (82)
- CD68 (82)
- CTAG1B (81)
- CTNNB1 (80)
- VIM (80)
- GADD45G (78)
- LIPG (78)
- NBN (78)
- HAVCR2 (77)
- MSMB (77)
- OTC (75)
- PTPRC (74)
- CD44 (72)
- CD80 (72)
- CD99 (71)
- PCNA (70)
- NKX3-1 (69)
- LGALS3 (67)
- MS4A1 (67)
- PIK3C2A (66)
- ADIPOQ (65)
- AFP (65)
- CTLA4 (64)
- MDM2 (64)
- NUMB (64)
- VWF (64)
- CFI (63)
- MLANA (62)
- L1CAM (61)
- CD63 (60)
- TOP2A (60)
- CD47 (59)
- KRT20 (58)
- TNFRSF8 (58)
- MAPK13 (57)
- UBE2E3 (57)
- APP (56)
- CD33 (56)
- MAPT (55)
- NKX2-1 (55)
- F13A1 (54)
- PDCD1LG2 (54)
- SENP2 (54)
- BTLA (53)
- BCL2 (52)
- TYMS (52)
- MLH1 (51)
- PNMT (51)
- SERPINB3 (51)
- BRAF (49)
- CD27 (49)
- NCAM1 (49)
- SYP (49)
- TIGIT (49)
- ALDH1L1 (48)
- CD163 (48)
- CD19 (48)
- CHGA (48)
- MDM4 (48)
- MIEN1 (48)
- KIT (47)
- AKT1 (46)
- GFAP (46)
- LGR5 (46)
- FGF21 (45)
- PROCR (45)
- TACC2 (45)
- FOLH1 (44)
- MUC1 (44)
- PARVA (44)
- TNFRSF9 (43)
- BHLHE41 (42)
- ICOS (42)
- MGMT (42)
- RTRAF (42)
- SPG7 (42)
Reactivities
- Human (43847)
- Mouse (24920)
- Rat (23601)
- Monkey (2826)
- Dog (2428)
- Bovine (116)
- Hamster (85)
- Rabbit (85)
- Chicken (65)
- SARS-CoV-2 (63)
- Porcine (62)
- Primate (57)
- Canine (44)
- Pig (40)
- Sheep (31)
- Xenopus (29)
- Zebrafish (29)
- Guinea Pig (27)
- Drosophila (21)
- Chimpanzee (18)
- Escherichia coli (16)
- Mammalian (16)
- Cow (13)
- Frog (13)
- Feline (12)
- Goat (12)
- Yeast (12)
- C-term DDK (10)
- Fish (10)
- Macaque (10)
- All Species (9)
- Streptococcus Pyogenes (9)
- Virus (9)
- Equine (8)
- SARS-CoV (8)
- Saccharomyces cerevisiae (8)
- Baboon (6)
- C. elegans (6)
- Avian (5)
- Horse (5)
- Opossum (5)
- Cynomolgus (4)
- Ferret (4)
- Fruit fly (4)
- Insect (4)
- Rhesus Monkey (4)
- Amphibian (3)
- Beluga (3)
- HIV (3)
- Marmoset (3)
- Plant (3)
- Respiratory Syncytial Virus (3)
- Bacteria (2)
- Dengue virus (2)
- Dictyostelium (2)
- Drosophila melanogaster (2)
- West Nile Virus (2)
- Yellow Fever Virus (2)
- Bacillus Antracis (1)
- Broad (1)
- Carp (1)
- Chlamydomonas (1)
- Fungi (1)
- Helicobacter pylori (1)
- Salmonella Typhimurium (1)
- Spinach (1)
- Squirrel (1)
- Staphylococcus aureus (1)
- Trichinella spiralis (1)
- White Fly (1)
Applications
Antibody Hosts
Isotypes
- IgG1 (28459)
- IgG2a (7034)
- IgG2b (6208)
- IgG (1173)
- IgG1, kappa (534)
- IgG, kappa (372)
- IgG2a, kappa (163)
- IgG3 (135)
- IgG2b, kappa (100)
- IgM (78)
- IgG1, lambda (30)
- IgM, kappa (22)
- IgG3, kappa (16)
- IgG2c (12)
- IgG2a, lambda (11)
- IgG1-Fc Fusion (8)
- IgG2b, lambda (6)
- IgG4 (6)
- IgA-Fc Fusion (4)
- IgG-Fc Fusion (4)
- IgM-Fc Fusion (4)
- IgA (2)
- IgG2 (2)
- IgG2, kappa (2)
- scFv (2)
- IgA, kappa (1)
- IgG fraction (1)
- IgG1/IgK (1)
- IgG12b (1)
- IgG2, alpha (1)
- IgG3/IgG1 (1)
- cocktail (1)
Carrier-free
Knockout (KO) Validation
Modifications
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (94)
- This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. (40)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (36)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (27)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (23)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. (20)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (18)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human Fab format, for improved compatibility with existing reagents, assays and techniques. (17)
- Phospho-specific (16)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (15)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (15)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (14)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (14)
- This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. (12)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (8)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2a format, for improved compatibility with existing reagents, assays and techniques. (8)
- This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (8)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (6)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (6)
- This full-length, reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (6)
- This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (6)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (6)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric mouse antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (4)
- This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (4)
- Modification (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG2 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgM format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human scFv format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2b format, for improved compatibility with existing reagents, assays and techniques. (3)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (3)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric hamster (Armenian) antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric mouse antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This constant region of this antibody has been modified to bind to Protein A, allowing highly-specific purification of this antibody by Protein A-affinity column. (2)
- This full-length, chimeric mouse antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric murine antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Armenian Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Armenian Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This full-length, chimeric mouse antibody was made using the variable domain sequences of the original Chicken scFv format, for improved compatibility with existing reagents, assays and techniques. (1)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Chicken scFv format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric antibody created to reduce immunogenicity during in vivo applications. (1)
- This is a chimeric human antibody, based on the original mouse IgG2a format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric mouse antibody, based on the original hamster IgG format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric mouse antibody, based on the original rat IgG2b format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a reformatted human IgG1 antibody based on the therapeutic Fab fragment. NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (1)
- This is a reformatted mouse IgG1 antibody, based on the original mouse IgG2a format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted antibody was made using the variable domain sequences of the original mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted antibody was made using the variable domain sequences of the original rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original mouse scFv format for improved compatibility with existing reagents, assays and techniques. (1)
Assay Types
Assay Platforms
Families
- Druggable Genome (24050)
- Transmembrane (8224)
- Transcription Factors (6651)
- Secreted Protein (3903)
- ES Cell Differentiation/IPS (3475)
- Protein Kinase (2639)
- Protease (1830)
- Stem cell - Pluripotency (1579)
- Adult stem cells (888)
- Embryonic stem cells (576)
- Nuclear Hormone Receptor (571)
- Phosphatase (437)
- Cancer stem cells (398)
- Induced pluripotent stem cells (296)
- Stem cell relevant signaling - DSL/Notch pathway (263)
- Stem cell relevant signaling - JAK/STAT signaling pathway (207)
- P450 (197)
- Ion Channels: Other (182)
- GPCR (128)
- Stem cell relevant signaling - TGFb/BMP signaling pathway (96)
- Stem cell relevant signaling - Wnt Signaling pathway (40)
- Ion Channels: Potassium (34)
- Ion Channels: Transient receptor potential (24)
- Ion Channels: Cys-loop Receptors (18)
- Ion Channels: Sodium (9)
- Ion Channels: Calcium (4)
- Ion Channels: Glutamate Receptors (2)
- Ion Channels: Cyclic nucleotide gated (1)
Pathways
- Metabolic pathways (3900)
- Pathways in cancer (3014)
- MAPK signaling pathway (1951)
- Focal adhesion (1537)
- Cell adhesion molecules (CAMs) (1531)
- Prostate cancer (1468)
- T cell receptor signaling pathway (1419)
- Cytokine-cytokine receptor interaction (1332)
- Colorectal cancer (1221)
- Toll-like receptor signaling pathway (1198)
- Neurotrophin signaling pathway (1185)
- Hematopoietic cell lineage (1155)
- Melanoma (1150)
- Pancreatic cancer (1117)
- ErbB signaling pathway (1091)
- Bladder cancer (1085)
- Glioma (1052)
- Endometrial cancer (1031)
- Non-small cell lung cancer (1026)
- Chronic myeloid leukemia (1018)
- Regulation of actin cytoskeleton (1011)
- Cell cycle (986)
- B cell receptor signaling pathway (957)
- Progesterone-mediated oocyte maturation (955)
- Insulin signaling pathway (885)
- Endocytosis (839)
- Jak-STAT signaling pathway (837)
- GnRH signaling pathway (812)
- Fc epsilon RI signaling pathway (811)
- Apoptosis (809)
- Renal cell carcinoma (775)
- Natural killer cell mediated cytotoxicity (748)
- Acute myeloid leukemia (738)
- p53 signaling pathway (728)
- Leukocyte transendothelial migration (708)
- Chemokine signaling pathway (703)
- Wnt signaling pathway (695)
- Small cell lung cancer (694)
- Alzheimer's disease (673)
- Purine metabolism (665)
- VEGF signaling pathway (651)
- Fc gamma R-mediated phagocytosis (646)
- Thyroid cancer (624)
- Gap junction (616)
- Adherens junction (588)
- Amyotrophic lateral sclerosis (ALS) (581)
- Oocyte meiosis (573)
- Pyrimidine metabolism (567)
- Ubiquitin mediated proteolysis (564)
- Huntington's disease (556)
- Primary immunodeficiency (517)
- Melanogenesis (506)
- Epithelial cell signaling in Helicobacter pylori infection (496)
- Adipocytokine signaling pathway (476)
- Calcium signaling pathway (474)
- Complement and coagulation cascades (455)
- Type II diabetes mellitus (455)
- mTOR signaling pathway (451)
- Autoimmune thyroid disease (432)
- Systemic lupus erythematosus (432)
- Basal cell carcinoma (418)
- Long-term depression (412)
- Antigen processing and presentation (406)
- Long-term potentiation (398)
- Axon guidance (397)
- Glycolysis / Gluconeogenesis (394)
- Pathogenic Escherichia coli infection (389)
- Tight junction (388)
- NOD-like receptor signaling pathway (384)
- Vascular smooth muscle contraction (372)
- Arginine and proline metabolism (368)
- RIG-I-like receptor signaling pathway (367)
- Parkinson's disease (358)
- Prion diseases (358)
- Viral myocarditis (357)
- Lysosome (352)
- ECM-receptor interaction (346)
- Allograft rejection (335)
- Nucleotide excision repair (329)
- Type I diabetes mellitus (324)
- TGF-beta signaling pathway (310)
- Dorso-ventral axis formation (304)
- Valine (296)
- leucine and isoleucine degradation (289)
- Hedgehog signaling pathway (285)
- Graft-versus-host disease (284)
- Oxidative phosphorylation (282)
- Hypertrophic cardiomyopathy (HCM) (275)
- Proteasome (267)
- PPAR signaling pathway (265)
- Cytosolic DNA-sensing pathway (262)
- Dilated cardiomyopathy (260)
- Tryptophan metabolism (252)
- Glycerolipid metabolism (251)
- RNA degradation (241)
- Lysine degradation (239)
- Phosphatidylinositol signaling system (233)
- Propanoate metabolism (225)
- Arachidonic acid metabolism (222)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) (222)
- Spliceosome (220)
- Drug metabolism - cytochrome P450 (219)
- One carbon pool by folate (218)
- Pyruvate metabolism (214)
- Neuroactive ligand-receptor interaction (213)
- Metabolism of xenobiotics by cytochrome P450 (212)
- Fatty acid metabolism (209)
- Inositol phosphate metabolism (209)
- Alanine (206)
- Mismatch repair (206)
- aspartate and glutamate metabolism (206)
- DNA replication (202)
- Histidine metabolism (202)
- Glutathione metabolism (198)
- Tyrosine metabolism (197)
- Notch signaling pathway (180)
- Butanoate metabolism (176)
- Base excision repair (170)
- beta-Alanine metabolism (167)
- Glycine (155)
- serine and threonine metabolism (155)
- Drug metabolism - other enzymes (149)
- Renin-angiotensin system (149)
- ABC transporters (145)
- Asthma (145)
- Cardiac muscle contraction (141)
- Maturity onset diabetes of the young (140)
- Retinol metabolism (140)
- Fructose and mannose metabolism (135)
- Vibrio cholerae infection (135)
- Circadian rhythm - mammal (125)
- Homologous recombination (125)
- Cysteine and methionine metabolism (123)
- Starch and sucrose metabolism (122)
- Amino sugar and nucleotide sugar metabolism (120)
- Linoleic acid metabolism (106)
- Nicotinate and nicotinamide metabolism (105)
- Citrate cycle (TCA cycle) (98)
- SNARE interactions in vesicular transport (98)
- Pentose phosphate pathway (96)
- Regulation of autophagy (94)
- Glycerophospholipid metabolism (88)
- RNA polymerase (86)
- Terpenoid backbone biosynthesis (86)
- Porphyrin and chlorophyll metabolism (85)
- Sphingolipid metabolism (81)
- Folate biosynthesis (79)
- Sulfur metabolism (78)
- Aminoacyl-tRNA biosynthesis (77)
- Nitrogen metabolism (77)
- Galactose metabolism (76)
- Ribosome (74)
- Primary bile acid biosynthesis (73)
- Ascorbate and aldarate metabolism (70)
- Caffeine metabolism (69)
- Other glycan degradation (69)
- Methane metabolism (67)
- Fatty acid elongation in mitochondria (66)
- N-Glycan biosynthesis (61)
- Non-homologous end-joining (56)
- Glyoxylate and dicarboxylate metabolism (55)
- Selenoamino acid metabolism (50)
- Phenylalanine metabolism (49)
- Basal transcription factors (48)
- Cyanoamino acid metabolism (44)
- Androgen and estrogen metabolism (43)
- Synthesis and degradation of ketone bodies (43)
- Ether lipid metabolism (42)
- Thiamine metabolism (42)
- Olfactory transduction (41)
- Limonene and pinene degradation (40)
- Glycosaminoglycan degradation (33)
- Taste transduction (33)
- C21-Steroid hormone metabolism (28)
- Pantothenate and CoA biosynthesis (25)
- Fatty acid biosynthesis (23)
- Biosynthesis of unsaturated fatty acids (22)
- Glycosphingolipid biosynthesis - lacto and neolacto series (21)
- Riboflavin metabolism (20)
- Keratan sulfate biosynthesis (18)
- Pentose and glucuronate interconversions (18)
- Vitamin B6 metabolism (18)
- alpha-Linolenic acid metabolism (18)
- Glycosphingolipid biosynthesis - ganglio series (15)
- Steroid biosynthesis (13)
- Glycosphingolipid biosynthesis - globo series (12)
- leucine and isoleucine biosynthesis (10)
- D-Glutamine and D-glutamate metabolism (9)
- Phenylalanine (9)
- Taurine and hypotaurine metabolism (9)
- tyrosine and tryptophan biosynthesis (9)
- O-Glycan biosynthesis (6)
- Protein export (6)
- Biotin metabolism (3)
- Ubiquinone and other terpenoid-quinone biosynthesis (3)
- Chondroitin sulfate biosynthesis (2)
- Heparan sulfate biosynthesis (2)